Francesco Passamonti
Overview
Explore the profile of Francesco Passamonti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
300
Citations
11772
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Da Via M, Lazzaroni F, Matera A, Marella A, Maeda A, De Magistris C, et al.
Blood
. 2025 Feb;
PMID: 40009503
Multiple Myeloma is driven by clonal plasma cell (cPC)-intrinsic factors and changes in the tumorigenic microenvironment (TME). To investigate if residual polyclonal PCs (pPCs) are disrupted, single-cell (sc) RNAseq and...
2.
Bellani V, Mora B, Iurlo A, Passamonti F
Leuk Lymphoma
. 2025 Feb;
:1-13.
PMID: 39960832
Calreticulin (CALR) is a chaperone protein that plays a crucial role in protein folding quality control and calcium homeostasis. Mutations in result in a mutated protein lacking key calcium-binding sites...
3.
Fidanza C, Serpenti F, Cavallaro F, Barbullushi K, Rampi N, Rossi Dardanoni F, et al.
Blood Adv
. 2025 Feb;
PMID: 39913922
No abstract available.
4.
Guglielmelli P, Ghirardi A, Carobbio A, Masciulli A, Morrone L, Mora B, et al.
Hemasphere
. 2025 Feb;
9(2):e70072.
PMID: 39897086
No abstract available.
5.
Passamonti F, Korgaonkar S, Parikh R, Chevli M, Yucel A, Rombi J, et al.
Future Oncol
. 2025 Jan;
21(5):579-591.
PMID: 39865562
Aim: Assess real-world fedratinib (FEDR) treatment patterns and clinical outcomes in patients with primary or secondary myelofibrosis following discontinuation of ruxolitinib (RUX). Patients & Methods: This study was a retrospective,...
6.
Harrison C, Mesa R, Talpaz M, Gupta V, Gerds A, Perkins A, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Nov;
25(3):199-211.
PMID: 39516087
Purpose: Anemia is a cardinal feature of myelofibrosis often managed with red blood cell (RBC) transfusions, which may contribute to negative prognostic, quality-of-life, and healthcare-related economic impacts. The Janus kinase...
7.
Breccia M, Celant S, Palandri F, Passamonti F, Olimpieri P, Summa V, et al.
Br J Haematol
. 2024 Oct;
206(1):172-179.
PMID: 39363576
Ruxolitinib is a JAK1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF)-related splenomegaly or symptoms. The recommended starting dose depends on platelet count, regardless of haemoglobin level at baseline. In...
8.
Fattizzo B, Bosi A, Sorrenti M, Murgia D, Pettine L, Bortolotti M, et al.
Sci Rep
. 2024 Sep;
14(1):21891.
PMID: 39300133
Chronic idiopathic neutropenia (CIN) is a rare benign condition caused by an immune attack against neutrophils, either primary or in the context of other autoimmune conditions, lymphoproliferative syndromes, and inborn...
9.
Harrison C, Mesa R, Talpaz M, Al-Ali H, Xicoy B, Passamonti F, et al.
Lancet Haematol
. 2024 Sep;
11(10):e729-e740.
PMID: 39265613
Background: Most patients with myelofibrosis develop ruxolitinib intolerance or disease that is relapsed or refractory, and survival rates after ruxolitinib discontinuation are poor. We aimed to evaluate the safety and...
10.
Mora B, Bucelli C, Cattaneo D, Bellani V, Versino F, Barbullushi K, et al.
Curr Hematol Malig Rep
. 2024 Aug;
19(5):223-235.
PMID: 39179882
Purpose Of Review: Myelofibrosis (MF) includes prefibrotic primary MF (pre-PMF), overt-PMF and secondary MF (SMF). Median overall survival (OS) of pre-PMF, overt-PMF and SMF patients is around 14 years, seven...